Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Sublingual 5-MeO-DMT for Anxiety and Depression
NCT06816667Phase 2Completed
- Sponsor
- Biomind Labs
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 5-MeO-DMT in anxiety disorder and major depressive disorder (MDD) (4 arms), sponsored by Biomind Labs. Primary endpoints: Number of participants with Adverse Events Coded by MedDRA at 6 weeks, Maximum Plasma Concentration and 6 more. Started Oct 2024; status: completed.
02
Drugs
5-MeO-DMT
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06816667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816667.